SAFC Manufacturing New High-Quality PharmaGrade Raw Materials at Arklow, Ireland, Plant
Sigma-Aldrich Corporation’s custom manufacturing services business unit, SAFC Commercial, has broadened production at its Arklow, Ireland, facility to include new PharmaGrade products. Production of the raw materials began at the site earlier this year and complements the existing offering of highly regulated active and non-active pharmaceutical ingredients manufactured at the site. All products manufactured at the Arklow facility meet and exceed FDA regulations; follow cGMPs for biopharmaceutical production; and comply with International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) requirements.
“Arklow was chosen for this expansion due to its existing specialised and highly regulated manufacturing capability,” said James Ennis, Site Manager for SAFC’s Arklow Facility. “All PharmaGrade products offer high purity and are manufactured under controlled processes. The PharmaGrade products from Arklow are manufactured under ICH Q7 guidelines."
The new PharmaGrade products manufactured at the Arklow facility include difficult-to-source materials available from research- to commercial-scale volumes. The programme takes advantage of Arklow’s purification, recrystallisation and distillation competencies to manufacture a short list of catalog products in the PharmaGrade line, including benzyl alcohol, ethanolamine, fumaric acid, N-acetyl-DL-tryptophan, sodium benzoate, sodium butyrate and hexylene glycol. These specific products began transitioning to the Arklow facility in Q4 of 2011 and were then upgraded to meet PharmaGrade guidelines before production began this year. There are plans to further expand the PharmaGrade product offering from Arklow with D-galactose expected to launch in Q4 of 2013.
“With the addition of products being made in Arklow, the PharmaGrade line now encompasses almost 100 products that offer the right quality for our biopharma and pharma customers, as well as providing additional value through quality documentation packages, readily-available inventory and multiple batches to support customer qualification activities,” said Douglas Bowman, SAFC’s Program Manager for PharmaGrade.
SAFC’s Arklow facility was originally purpose-built for products that require alkylation, esterification, ester condensation, reduction and Suzuki coupling, and features additional chromatography, crystallization and milling capabilities. With 64,000 m3 of space, the Arklow facility is fully cGMP compliant and has consistently passed FDA and Irish Medicines Board (IMB) inspections. It features four separate plants and has reactor capacity of more than 94,000 L, including glass-lined, as well as stainless steel reactors, distillation units, various dryers and ovens and controlled sieving, delumping and packaging space.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance